Canerpaturev - Takara Bio

Drug Profile

Canerpaturev - Takara Bio

Alternative Names: C-REV; HF-10; Msc-2; TBI-1401

Latest Information Update: 30 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio; University of Utah
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Pancreatic cancer
  • No development reported Head and neck cancer; Solid tumours

Most Recent Events

  • 21 Oct 2018 Positive top-line efficacy and adverse events data from a phase II trial in Malignant melanoma presented at the European Society for Medical Oncology Annual Meeting (ESMO-2018)
  • 19 Oct 2018 Takara Bio announces intention to submit NDA for Malignant melanoma
  • 05 Jun 2018 Takara Bio completes a phase II trial in Malignant melanoma (Late-stage disease, Inoperable/unresectable, Metastatic disease, Combination therapy) in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top